Heterogeneity of violence in schizophrenia and implications for long-term treatment

International Journal of Clinical Practice

Volumn 62, Issue 8, 2008, Pages 1237-1245

  Volavka, J ^a,b   Citrome, L ^b,c  

^a New York University School of Medicine ^*  (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

ADJUVANT THERAPY; AGGRESSION; BEHAVIOR DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DELUSION; DISEASE EXACERBATION; DRUG EFFICACY; HALLUCINATION; HOSTILITY; HUMAN; IMPULSIVENESS; LONG TERM CARE; MEDLINE; MONOTHERAPY; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOPATHY; PSYCHOSIS; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SUBSTANCE ABUSE; TREATMENT DURATION; TREATMENT OUTCOME; VIOLENCE;

AGGRESSION; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; LITHIUM; LONG-TERM CARE; MALE; PERSONALITY DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; VIOLENCE;

EID: 47149103828     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01797.x     Document Type: Review

References (84)

1. Volavka J. Neurobiology of Violence, 2nd edn. Washington, DC : American Psychiatric Publishing, Inc., 2002.
2. Convit A, Isay D, Otis D, Volavka J. Characteristics of repeatedly assaultive psychiatric inpatients. Hosp Community Psychiatry 1990 41 : 1112 5.
3. Owen C, Tarantello C, Jones M, Tennant C. Violence and aggression in psychiatric units. Psychiatr Serv 1998 49 : 1452 7.
4. Fazel S, Grann M. The population impact of severe mental illness on violent crime. Am J Psychiatry 2006 163 : 1397 403.
5. Volavka J, Citrome L. Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns. Schizophr Res 1999 35 : S23 33.
6. Citrome L. Creating a more productive, clutter-free, paperless office: a primer on scanning, storage and searching of PDF documents on personal computers. Int J Clin Pract 2008 62 : 363 6.
7. McEvoy JP, Scheifler PL, Frances A. The expert consensus guideline series. Treatment of schizophrenia. J Clin Psychiatry 1999 11 : 1 80.
8. Kane JM, Leucht S, Carpenter D, Docherty JP. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003 64 (Suppl. 12 1 100.
9. Junginger J. Command hallucinations and the prediction of dangerousness. Psychiatr Serv 1995 46 : 911 4.
10. McNiel DE, Eisner JP, Binder RL. The relationship between command hallucinations and violence. Psychiatr Serv 2000 51 : 1288 92.
11. Zisook S, Byrd D, Kuck J, Jeste DV. Command hallucinations in outpatients with schizophrenia. J Clin Psychiatry 1995 56 : 462 5.
12. Link BG, Stueve A. Psychotic symptoms and the violent/illegal behavior of mental patients compared to community controls. In : Monahan J, Steadman HJ, eds. Violence and Mental Disorder. Developments in Risk Assessment. Chicago, IL : The University of Chicago Press, 1994 : pp. 137 59.
13. Link BG, Stueve A, Phelan J. Psychotic symptoms and violent behaviors: probing the components of 'threat/control-override' symptoms. Soc Psychiatry Psychiatr Epidemiol 1998 33 (Suppl. 1 S55 60.
14. Appelbaum PS, Robbins PC, Monahan J. Violence and delusions: data from the MacArthur Violence Risk Assessment Study. Am J Psychiatry 2000 157 : 566 72.
15. Link BG, Cullen FT, Andrews H. The violent and illegal behavior of mental patients reconsidered. Am Sociol Rev 1992 57 : 275 92.
16. Nolan KA, Volavka J, Czobor P et al. Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder. J Psychiatr Res 2005 39 : 109 15.
17. Nolan KA, Czobor P, Roy BB et al. Characteristics of assaultive behavior among psychiatric inpatients. Psychiatr Serv 2003 54 : 1012 6.
18. Kiehl KA, Smith AM, Hare RD, Liddle PF. An event-related potential investigation of response inhibition in schizophrenia and psychopathy. Biol Psychiatry 2000 48 : 210 21.
19. Barratt ES. Measuring and predicting aggression within the context of a personality theory. J Neuropsychiatry Clin Neurosci 1991 3 : S35 9.
20. Hoptman MJ, Volavka J, Johnson G, Weiss E, Bilder RM, Lim KO. Frontal white matter microstructure, aggression, and impulsivity in men with schizophrenia: a preliminary study. Biol Psychiatry 2002 52 : 9 14.
21. Hoptman MJ, Ardekani BA, Butler PD, Nierenberg J, Javitt DC, Lim KO. DTI and impulsivity in schizophrenia: a first voxelwise correlational analysis. Neuroreport 2004 15 : 2467 70.
22. Hare RD. Psychopathy and antisocial personality disorder: a case of diagnostic confusion. Psychiatric Times 1996 13 : 39 40.
23. Nolan KA, Citrome L, Volavka J. Violence in schizophrenia: the roles of psychosis and psychopathy. J Pract Psychiatry Behav Health 1999 5 : 326 35.
24. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 353 : 1209 23.
25. Swanson JW, Van Dorn RA, Swartz MS, Smith A, Elbogen EB, Monahan J. Alternative pathways to violence in persons with schizophrenia: the role of childhood antisocial behavior problems. Law Hum Behav 2008 32 : 228 40.
26. Bender L. The concept of pseudopsychopathic schizophrenia in adolescents. Am J Orthopsychiatry 1959 29 : 491 512.
27. Rasmussen K, Levander S. Symptoms and personality characteristics of patients in a maximum security psychiatric unit. Int J Law Psychiatry 1996 19 : 27 37.
28. Moran P, Walsh E, Tyrer P, Burns T, Creed F, Fahy T. Impact of comorbid personality disorder on violence in psychosis: report from the UK700 trial. Br J Psychiatry 2003 182 : 129 34.
29. Sugden SG, Kile SJ, Hendren RL. Neurodevelopmental pathways to aggression: a model to understand and target treatment in youth. J Neuropsychiatry Clin Neurosci 2006 18 : 302 17.
30. Regier DA, Farmer ME, Rae DS et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990 264 : 2511 8.
31. Swartz MS, Wagner HR, Swanson JW et al. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis 2006 194 : 164 72.
32. Swartz MS, Swanson JW, Hiday VA, Borum R, Wagner R, Burns BJ. Taking the wrong drugs: the role of substance abuse and medication noncompliance in violence among severely mentally ill individuals. Soc Psychiatry Psychiatr Epidemiol 1998 33 (Suppl. 1 S75 80.
33. Ascher-Svanum H, Zhu B, Faries D, Lacro JP, Dolder CR. A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J Clin Psychiatry 2006 67 : 1114 23.
34. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002 159 : 103 8.
35. Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006 67 : 453 60.
36. Alia-Klein N, O'Rourke TM, Goldstein RZ, Malaspina D. Insight into illness and adherence to psychotropic medications are separately associated with violence severity in a forensic sample. Aggress Behav 2007 33 : 86 96.
37. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988 45 : 789 96.
38. Maier GJ. The impact of clozapine on 25 forensic patients. Bull Am Acad Psychiatry Law 1992 20 : 297 307.
39. Wilson WH. Clinical review of clozapine treatment in a state hospital. Hosp Community Psychiatry 1992 43 : 700 3.
40. Mallya AR, Roos PD, Roebuck-Colgan K. Restraint, seclusion, and clozapine. J Clin Psychiatry 1992 53 : 395 7.
41. Chiles JA, Davidson P, McBride D. Effects of clozapine on use of seclusion and restraint at a state hospital. Hosp Community Psychiatry 1994 45 : 269 71.
42. Ebrahim GM, Gibler B, Gacono CB, Hayes G. Patient response to clozapine in a forensic psychiatric hospital. Hosp Community Psychiatry 1994 45 : 271 3.
43. Volavka J, Zito JM, Vitrai J, Czobor P. Clozapine effects on hostility and aggression in schizophrenia. J Clin Psychopharmacol 1993 13 : 287 9.
44. Buckley P, Bartell J, Donenwirth K, Lee S, Torigoe F, Schulz SC. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law 1995 23 : 607 11.
45. Bitter I, Czobor P, Dossenbach M, Volavka J. Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO). Eur Psychiatry 2005 20 : 403 8.
46. Citrome L, Volavka J, Czobor P et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility in treatment-resistant patients with schizophrenia and schizoaffective disorder. Psychiatr Serv 2001 52 : 1510 4.
47. Volavka J, Czobor P, Nolan K et al. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychopharmacol 2004 24 : 225 8.
48. Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2006 63 : 622 9.
49. Kay SR, Wolkenfeld F, Murrill LM. Profiles of aggression among psychiatric patients. I. Nature and prevalence. J Nerv Ment Dis 1988 176 : 539 46.
50. Beck NC, Greenfield SR, Gotham H, Menditto AA, Stuve P, Hemme CA. Risperidone in the management of violent, treatment-resistant schizophrenics hospitalized in a maximum security forensic facility. J Am Acad Psychiatry Law 1997 25 : 461 8.
51. Buckley PF, Ibrahim ZY, Singer B, Orr B, Donenwirth K, Brar PS. Aggression and schizophrenia: efficacy of risperidone. J Am Psychiatry Law 1997 25 : 173 81.
52. Chengappa KN, Levine J, Ulrich R et al. Impact of risperidone on seclusion and restraint at a state psychiatric hospital. Can J Psychiatry 2000 45 : 827 32.
53. Citrome L, Shope CB, Nolan KA, Czobor P, Volavka J. Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. Int Clin Psychopharmacol 2007 22 : 356 62.
54. Czobor P, Volavka J, Meibach RC. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 1995 15 : 243 9.
55. Swanson JW, Swartz MS, VanDorn RA, Volavka J, Monahan J, Stroup S et al. Medication effects on reducing violence in persons with schizophrenia. Br J Psychiatry 2008 (in press).
56. Swanson JW, Swartz MS, Elbogen EB, Van Dorn RA. Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. J Clin Psychiatry 2004 65 : 1666 73.
57. Chengappa KN, Goldstein JM, Greenwood M, John V, Levine J. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Ther 2003 25 : 530 41.
58. Arango C, Bernardo M. The effect of quetiapine on aggression and hostility in patients with schizophrenia. Hum Psychopharmacol 2005 20 : 237 41.
59. Volavka J, Czobor P, Citrome L et al. Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. J Clin Psychiatry 2005 66 : 1362 6.
60. Citrome L, Volavka J, Czobor P, Brook S, Loebel A, Mandel FS. Efficacy of ziprasidone against hostility in schizophrenia: post hoc analysis of randomized, open-label study data. J Clin Psychiatry 2006 67 : 638 42.
61. Citrome L, Jaffe A, Levine J. Datapoints-mood stabilizers: utilization trends in patients diagnosed with schizophrenia 1994-2001. Psychiatr Serv 2002 53 : 1212.
62. Citrome L. Antiepileptics in the treatment of schizophrenia. In : McElroy SL, Keck PE Jr, Post RM, eds. Antiepileptic Drugs to Treat Psychiatric Disorders. New York : Informa Healthcare, Inc., 2008, pp. 187 206.
63. Citrome L. Use of lithium, carbamazepine, and valproic acid in a state-operated psychiatric hospital. J Pharm Technol 1995 11 : 55 9.
64. Hollander E, Grossman R, Stein DJ, Kwon J. Borderline personality disorder and impulsive-aggression: the role for divalproex sodium treatment. Psychiatr Ann Suppl 1996 26 : S464 9.
65. Kavoussi RJ, Coccaro EF. Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. J Clin Psychiatry 1998 59 : 676 80.
66. Stanford MS, Helfritz LE, Conklin SM et al. A comparison of anticonvulsants in the treatment of impulsive aggression. Exp Clin Psychopharmacol 2005 13 : 72 7.
67. Hollander E, Allen A, Lopez RP et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001 62 : 199 203.
68. Hollander E, Tracy KA, Swann AC et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 2003 28 : 1186 97.
69. Lindenmayer J-P, Kotsaftis A. Use of sodium valproate in violent and aggressive behaviors: a critical review. J Clin Psychiatry 2000 61 : 123 8.
70. Kelly DL, Conley RR, Feldman S, Yu Y, McMahon RP, Richardson CM. Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. Psychiatr Q 2006 77 : 81 95.
71. Citrome L, Casey DE, Daniel DG, Wozniak P, Kochan LD, Tracy KA. Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Psychiatr Serv 2004 55 : 290 4.
72. Okuma T, Yamashita I, Takahashi R et al. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatr Scand 1989 80 : 250 9.
73. Leucht S, McGrath J, White P, Kissling W. Carbamazepine augmentation for schizophrenia: how good is the evidence? J Clin Psychiatry 2002 63 : 218 24.
74. Tiihonen J, Hallikainen T, Ryynanen OP et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 2003 54 : 1241 8.
75. Goff DC, Keefe R, Citrome L et al. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol 2007 27 : 582 9.
76. Collins PJ, Larkin EP, Shubsachs AP. Lithium carbonate in chronic schizophrenia - a brief trial of lithium carbonate added to neuroleptics for treatment of resistant schizophrenic patients. Acta Psychiatr Scand 1991 84 : 150 4.
77. Garmendia L, Sanchez JR, Azpiroz A, Brain PF, Simon VM. Clozapine: strong antiaggressive effects with minimal motor impairment. Physiol Behav 1992 51 : 51 4.
78. Kraus JE, Sheitman BB. Clozapine reduces violent behavior in heterogeneous diagnostic groups. J Neuropsychiatry Clin Neurosci 2005 17 : 36 44.
79. Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000 26 : 441 9.
80. Spivak B, Shabash E, Sheitman B, Weizman A, Mester R. The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. J Clin Psychiatry 2003 64 : 755 60.
81. Hart SD, Hare RD, Forth AE. Psychopathy as a risk marker for violence: development and validation of a screening version of the revised psychopathy checklist. In : Monahan J, Steadman HJ, eds. Violence and Mental Disorder. Developments in Risk Assessment. Chicago, IL : The University of Chicago Press, 1994 : pp. 81 98.
82. Hare RD, Neumann CS. Psychopathy as a clinical and empirical construct. Annu Rev Clin Psychol 2008 4 : 217 46.
83. Kunz M, Yates KF, Czobor P, Rabinowitz S, Lindenmayer JP, Volavka J. Course of patients with histories of aggression and crime after discharge from a cognitive-behavioral program. Psychiatr Serv 2004 55 : 654 9.
84. Yates K, Kunz M, Czobor P, Rabinowitz S, Lindenmayer JP, Volavka J. A cognitive, behaviorally based program for patients with persistent mental illness and a history of aggression, crime, or both: structure and correlates of completers of the program. J Am Acad Psychiatry Law 2005 33 : 214 22.